SCHEMBL144351

SCHEMBL144351

Cc1ccc(Br)cc1C=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.57
ALDH1A1 P00352 3/20 0.48
TSHR P16473 1/20 0.48
CYP2A6 P11509 3/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
PTPN1 P18031 1/20 0.41
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA3 P42263 1/20 0.39
GRIA4 P48058 1/20 0.39
PIM3 Q86V86 2/20 0.37
PRKDC P78527 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PIM1 P11309 1/20 0.36
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401340 1.00 ERN1 (0.57) ERN1ALDH1A1TSHRCYP2A6PTGDR2
Ethylene Glycol SCHEMBL28495626 0.90 ERN1 (0.53) ERN1ALDH1A1TSHRCYP2A6PTGDR2
SCHEMBL1277178 0.82 ERN1 (0.52) ERN1ALDH1A1TSHRCYP2A6PTGDR2
SCHEMBL3040456 0.78 ERN1 (0.64) ERN1ALDH1A1CYP2A6PTGDR2PTPN1
SCHEMBL16953358 0.77 ERN1 (0.38) ERN1ALDH1A1TSHRSMN1; SMN2CA12
SCHEMBL20194894 0.77 ERN1 (0.38) ERN1ALDH1A1TSHRSMN1; SMN2CA12
SCHEMBL16958010 0.77 ERN1 (0.42) ERN1ALDH1A1TSHRSMN1; SMN2CA12
SCHEMBL28805073 0.77 ERN1 (0.38) ERN1ALDH1A1TSHRCYP2A6PTGDR2
SCHEMBL268706 0.76 ALDH1A1 (0.52) ERN1ALDH1A1TSHRCYP2A6GRIA1
SCHEMBL414267 0.76 ERN1 (0.61) ERN1ALDH1A1CYP2A6PTGDR2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059975-A Eight-membered ring condensed boron dipyrrole compound and preparation method thereof 中国科学院宁波材料技术与工程研究所 2026-05-19 CN claimed
CN-112028917-A Preparation method of 3-aldehyde-4-methyl phenylboronic acid 珠海奥博凯生物医药技术有限公司 2020-12-04 CN claimed
CN-108084448-B Cadmium polymerization complex containing 4, 5-dimethyl-1, 2-phenylenediamine derivative and preparation method and application thereof 湘潭大学 2020-10-30 CN claimed
CN-108047262-A A kind of preparation method of 3- aldehyde radicals -4- methylphenylboronic acids 珠海奥博凯生物医药技术有限公司 2018-05-18 CN claimed
CN-122059975-A Eight-membered ring condensed boron dipyrrole compound and preparation method thereof 中国科学院宁波材料技术与工程研究所 2026-05-19 CN disclosed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
US-12617777-B2 GPR84 antagonists and uses thereof Liminal Biosciences Limited (GB) 2026-05-05 US disclosed
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-12-25 US disclosed
US-20250361210-A1 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2025-11-27 US disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
WO-2025085554-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 WO disclosed
WO-2025085564-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 WO disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 US disclosed
WO-2005058943-A1 BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES AICURIS GMBH & CO. KG (DE) 2005-06-30 WO disclosed
WO-2005051911-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2005-06-09 WO disclosed
WO-2005012326-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2005-02-10 WO disclosed
US-20040167193-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-26 US disclosed
US-6762197-B2 FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-07-13 US disclosed
US-20030119670-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-26 US disclosed
EP-1238975-A1 DIFLUOROMETHYLTRIAZOLONE COMPOUNDS, USE OF THE SAME AND INTERMEDIATES FOR THE PRODUCTION THEREOF Sumitomo Chemical Company, Limited (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 ERN1 2429/4885ALDH1A1 831/4885TSHR 3847/4885
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, FFAR3 ERN1 1789/4885ALDH1A1 3776/4885TSHR 64/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB ERN1 314/4885ALDH1A1 4167/4885TSHR 4220/4885
US-12617777-B2 GPR84 antagonists and uses thereof GPR84, GPR88, GPR3 ERN1 2787/4885ALDH1A1 2463/4885TSHR 303/4885
US-20040167193-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof CYP51A1, DPM1, CYP1A1 ERN1 920/4885ALDH1A1 466/4885TSHR 2768/4885
US-20250361210-A1 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND TSHR, TRHR, GHSR ERN1 3831/4885ALDH1A1 1515/4885TSHR 1/4885
US-20030119670-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof CYP51A1, DPM1, CYP1A1 ERN1 920/4885ALDH1A1 466/4885TSHR 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.